Adverse drug reactions and adverse events of 33 varieties of traditional Chinese medicine injections on National Essential medicines List (2004 edition) of China: An overview on published literatures

Journal of Evidence-Based Medicine

Volumn 3, Issue 2, 2010, Pages 95-104

  Wang, Li ^a   Yuan, Qiang ^a   Marshall, Gareth ^a   Cui, Xiaohua ^a   Cheng, Lan ^a   Li, Yuanyuan ^a   Shang, Hongcai ^b   Zhang, Boli ^b   Li, Youping ^a  

^a SICHUAN UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Adverse drug reaction; Adverse event; Essential medicine; Traditional Chinese medicine injections

Indexed keywords

CHINESE DRUG; CIWUJIA; DENGZHANHUASU; HUANGQI; LIANBIZHI; QINGKAILING; SALVIA MILTIORRHIZA EXTRACT; SHENGMAIYIN; SHENMAI; SHUANGHUANGLIAN; UNCLASSIFIED DRUG; YINZHIHUANG; YUXINGCAO;

DRUG SAFETY; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AWARENESS; CHINA; DRUGS, ESSENTIAL; HUMANS; MEDICINE, CHINESE TRADITIONAL;

EID: 77954617989     PISSN: 17565383     EISSN: 17565391     Source Type: Journal    
DOI: 10.1111/j.1756-5391.2010.01073.x     Document Type: Review

References (26)

1. Zhou Chao-fan. The warning from adverse reaction of Chinese medicine injections. Chinese Traditional Medicine 2008. Available from: URL: http://www.zgmjzyy.com/html/ 256/6/6002/1.htm.
2. The speech about safety re-evaluation for Chinese medicine injection was said by Wu Zhen on the television and telephone conference, the deputy director of the State Food and Drug Administration. 2009. Available from: URL: http://www.sda.gov.cn/WS01/CL0049/ 39953.html.
3. The varieties of Chinese medicine on the National Essential Drug List (2004 edition). Available from: URL: http://law.pharmnet.com.cn/upload/ 0503311130112263.pdf.
4. The State Food and Drug Administration. ShuangHuanglian injection and its hypersensitivity. Newsletter of Adverse Drug Reactions 2001; 1.
5. The Ministry of Health Press Office. The Ministry of Health and the SFDA noticed on an emergency that the ShuangHuanglian injection produced by Ussuri River Pharmaceutical Co., Ltd. in Heilongjiang Jiamusi must be stopped for use. 2009.
6. The SFDA. Public warning about the serious ADR of ShuangHuanglian injection. Newsletter of Adverse Drug Reactions 2009; 22.
7. The SFDA. A Urgent Notice about Suspension of Sale and Using the ShuangHuanglian Branded by DuoDuo Pharmaceutical Co., Ltd. The 12th document published by the SFDA (2009). 2009. Available from: URL: http://www.sda.gov.cn/ WS01/CL0055/41615.html.
8. The SFDA. QingKailing injection and its hypersensitivity. Newsletter of Adverse Drug Reactions 2001; 1.
9. The SFDA. Public warning about the serious ADR of QingKailing injection. Newsletter of Adverse Drug Reactions 2009; 21.
10. The SFDA. Public warning about the serious ADR of YuXingcao injection. Newsletter of Adverse Drug Reactions 2003; 4.
11. The SFDA. The SFDA make a decision about suspension of using and no more approval of registration of the seven kinds of YuXingcao injection. 2006. Available from: URL: http:// former.sfda.gov.cn/cmsweb/webportal/W3186/ A64009124.html.
12. The SFDA. A notice about allowing the YuJin muscle injection (2 ml) to be used which is produced by WanRong San Jiu Pharmaceutical Co., Ltd. The 674th document published by the SFDA (2009). 2009.
13. The Ministry of Healthy and SFDA. The Ministry of Health and the SFDA noticed on an emergency that the CiWujia injection produced by WanDashan Pharmaceutical must be suspended for using and sale. 2008.
14. The Ministry of Healthy. A urgent telephone conference hold by the Ministry of Healthy about emergency stoppage of clinical using the YinZhihuang injection. 2008. Available from: URL: http://www.hlj.gov.cn/kx/200810/t20081020- 137602.htm
15. The SFDA. The ADR about Shen-Mai injection. Communication of Information on Adverse Drug Reactions 2003; 3.
16. The SFDA. LianBizhi injection and acute renal dysfunction. Newsletter of Adverse Drug Reactions 2004; 11: 22.
17. The SFDA. A notice about the amendment on the instruction of LianBizhi injection. The 576th document published by the SFDA (2006). 2006; 11: 12.
18. Juni P, Altman DG, Egger M. Assessing the quality of controlled trials. BMJ 2001; 323: 42-46.
19. Peking University Library "Guide to the Core Journals," 2008 version Editorial Board. Guide to the Core Journals (2008 edition). Available from: URL: http://www.llas.ac.cn/ upload/core journals.htm
20. A regular press conference in July which is hold by the SFDA. 2008. Available from: URL: http://www.sda.gov.cn/WS01/CL0329/31453-1.html
21. The speech about safety re-evaluation for Chinese medicine injection was said by Wu Zhen on the television and telephone conference, the deputy director of the State Food and Drug Administration. 2009. Available from: URL: http:// www.sda.gov.cn/WS01/CL0049/ 39953.html
22. John PA, Stepehn JW, Peter C, et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement. American College of Physicians 2004; 10(141): 781-788.
23. The SFDA. The methods and evaluation on how to monitor the ADR (3). 2007. Available from: URL: http://220.162.239.111/directory/web/WS01/CL0067/1071.html
24. Zhou J, Wu XY, Zhang YM, et al. Analysis of 5165 ADRs cases. Chinese Journal of Drug Application and Monitoring 2004; 1(1): 45-47.
25. The SFDA. A notice about regulations on the safety of CMI to carry out re-evaluation for CMI (The State Food Drug Administration's Office [2009]28). 2009.
26. The SFDA. A notice about doing well the safety re-evaluation work for CMI (The State Food Drug Administration's Office [2009] 359). 2009.